Cybin Inc. Announces Transfer of U.S. Listing to Nasdaq and Ticker Change to HELP

Cybin Inc., a clinical-stage pharmaceutical company focused on developing next-generation mental health treatments, has announced plans to voluntarily transfer its U.S. stock exchange listing from NYSE American to the Nasdaq Global Market. The company expects its common shares to cease trading on NYSE American at market close on January 4, 2026, and to begin trading on Nasdaq at market open on January 5, 2026. Concurrent with this move, the company's ticker symbol will change from "CYBN" to "HELP." Cybin will maintain its listing on Cboe Canada, where it will also trade under the "HELP" ticker beginning January 5, 2026.

This strategic move to Nasdaq, a premier global exchange known for technology and healthcare listings, could enhance Cybin's visibility and accessibility to a broader investor base. The ticker symbol change to HELP directly aligns with the company's stated mission of revolutionizing mental healthcare by developing new treatment options for people suffering from mental health conditions. The company describes itself as a late-stage breakthrough neuropsychiatry company addressing large unmet needs in mental healthcare.

Cybin's clinical development pipeline is central to its mission. The company is developing CYB003, a proprietary deuterated psilocin analog, which is in Phase 3 studies for the adjunctive treatment of major depressive disorder. This investigational drug has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration. Additionally, Cybin is developing CYB004, a proprietary deuterated N, N-dimethyltryptamine molecule, in a Phase 2 study for generalized anxiety disorder. The company also maintains a research pipeline of investigational compounds focused on 5-HT receptors.

The implications of this listing transfer extend beyond corporate finance. For the mental healthcare industry and patients, Cybin's progress represents a potential shift toward novel pharmacological treatments for conditions like major depressive disorder and generalized anxiety disorder, where current options may be insufficient for many. The company's focus on developing drugs intended to provide effective and durable results addresses a critical public health challenge. Founded in 2019, Cybin operates in Canada, the United States, the United Kingdom, and Ireland. The latest news and updates relating to the company are available in its newsroom at https://ibn.fm/CYBN.

This announcement was disseminated via InvestorWire, a specialized communications platform that is part of the Dynamic Brand Portfolio. InvestorWire provides services including wire-grade press release syndication, article and editorial syndication to over 5,000 outlets, enhanced press release services, and social media distribution. Full terms of use and disclaimers applicable to all content provided by InvestorWire are available on its website at https://www.InvestorWire.com/Disclaimer.